Sibila et al. [18] reported that 6-months post-COVID-19 patients with reduced DLCO levels presented higher levels of soluble intercellular adhesion molecule-1 (sICAM-1) and angiopoietin-2, suggesting persistent endothelial activation and damage. This evidence concerns the gene ANGPT2 and COVID-19.